A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies

导出原文传递

翻译打印收藏纠错

作者： Pardee,T.S. ^[1] ; Lee,K. ^[2] ; Luddy,J. ^[3] ; Maturo,C. ; Rodriguez,R. ; Isom,S. ; Miller,L.D. ; Stadelman,K.M. ; Levitan,D. ; Hurd,D. ; Ellis,L.R. ; Harrelson,R. ; Manuel,M. ; Dralle,S. ; Lyerly,S. ; Powell,B.L.

作者单位： Cornerstone Pharmaceuticals IncCranbury, NJ, United States ^[1] Cancer Biology, Comprehensive Cancer Center of Wake Forest UniversityWinston-Salem, NC, United ^[2] Internal Medicine, Section on Hematology and Oncology, Wake Forest Baptist HealthWinston-Salem, NC ^[3]

发布时间 2015-02-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Clinical cancer research

2014年20卷20期

5255-5264页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies

Clinical cancer research

相似文献

Clinical cancer research

相关期刊

检索历史清除